肺疾患エアロゾル送達デバイスの世界市場成長2024-2030年Global Pulmonary Disease Aerosol Delivery Devices Market Growth 2024-2030 肺疾患エアロゾルデリバリーデバイスは、喘息、慢性閉塞性肺疾患(COPD)、嚢胞性線維症などの呼吸器疾患の治療を容易にするために、エアロゾル化された粒子の形で肺に直接薬剤を投与するように設計された医療機... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー肺疾患エアロゾルデリバリーデバイスは、喘息、慢性閉塞性肺疾患(COPD)、嚢胞性線維症などの呼吸器疾患の治療を容易にするために、エアロゾル化された粒子の形で肺に直接薬剤を投与するように設計された医療機器である。これらの装置には、ネブライザー、定量吸入器(MDI)、ドライパウダー吸入器(DPI)などがあり、それぞれ正確な量の薬剤を効率的に供給するように調整されている。液体の薬剤を微細な霧やエアロゾルに変換することで、これらのデバイスは呼吸器官を介した迅速な吸収を可能にし、症状の迅速な緩和と肺機能の改善をもたらす。慢性呼吸器疾患の管理には不可欠であり、患者が最小限の全身的副作用で効果的かつ的を絞った治療を受けられるようにする。世界の肺疾患エアロゾル送達デバイス市場規模は、2024年の100万米ドルから2030年には100万米ドルに成長すると予測されており、2024年から2030年までの年平均成長率は%で推移すると予測されています。 LPインフォメーション社の最新リサーチレポート「肺疾患エアロゾル送達装置産業予測」は、過去の販売実績と2023年の肺疾患エアロゾル送達装置の世界総販売実績を調査し、2024年から2030年までの肺疾患エアロゾル送達装置の販売予測について地域別・市場分野別に包括的な分析を提供しています。肺疾患用エアロゾルデリバリーデバイスの売上高を地域別、市場分野別、サブセクター別に分類し、世界の肺疾患用エアロゾルデリバリーデバイス産業の詳細な分析を百万米ドル単位で提供しています。 このインサイトレポートでは、世界の肺疾患エアロゾルデリバリーデバイスの状況を包括的に分析し、製品セグメンテーション、企業形成、収益、市場シェア、最新開発、M&A活動に関する主要動向を明らかにします。また本レポートでは、肺疾患エアロゾルデリバリーデバイスのポートフォリオと能力、市場参入戦略、市場での地位、地理的な足跡に焦点を当てて、世界の主要企業の戦略を分析し、加速する世界の肺疾患エアロゾルデリバリーデバイス市場におけるこれらの企業の独自の地位をより良く理解しています。 この調査レポートは、肺疾患用エアロゾルデリバリーデバイスの世界的な見通しを形成する主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に予測を細分化して、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの定性的・定量的市場インプットに基づいた透明性の高い手法により、この調査予測は世界の肺疾患エアロゾルデリバリーデバイスの現状と将来の軌道について非常にニュアンスのある見解を提供します。 肺疾患用エアロゾルデリバリーデバイスの米国市場は、2023年の100万米ドルから2030年までに100万米ドルに増加し、2024年から2030年までの年平均成長率は%と推定される。 肺疾患エアロゾルデリバリーデバイスの中国市場は、2023年の百万米ドルから2030年には百万米ドルに、2024年から2030年までの年平均成長率は%と推定される。 肺疾患エアロゾルデリバリーデバイスのヨーロッパ市場は、2023年の百万米ドルから2030年には百万米ドルに、2024年から2030年までの年平均成長率は%と推定される。 世界の主要な肺疾患エアロゾルデリバリーデバイスプレーヤーは、グラクソ・スミスクライン(GSK)、アストラゼネカ、ベーリンガーインゲルハイム、マイラン、Viatrisなどをカバーする。売上高では、世界の2大企業が2023年にほぼ%のシェアを占めている。 のシェアを占めている。 当レポートでは、肺疾患エアロゾルデリバリーデバイス市場の包括的な概要、市場シェア、成長機会を、製品タイプ、用途、主要メーカー、主要地域、国別に紹介しています。 タイプ別セグメント 定量吸入器 乾燥粉末吸入器 ネブライザー 用途別セグメント 喘息 慢性閉塞性肺疾患(COPD) 嚢胞性線維症(CF) 特発性肺線維症(IPF) その他 本レポートではまた、市場を地域別に分けています: 南北アメリカ アメリカ カナダ メキシコ ブラジル APAC 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下の企業は、一次専門家から収集したインプットと、企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されている。 グラクソ・スミスクライン(GSK) アストラゼネカ ベーリンガーインゲルハイム マイラン ヴィアトリス ノバルティス アプターグループ キエシ・ファルマチェウティチ フィリップス テバ・ファーマシューティカル・インダストリーズ モナハン・メディカル オムロン PARIインターナショナル ベクチュラ H&Tプレスパート 本レポートで扱う主な質問 世界の肺疾患用エアロゾルデリバリーデバイス市場の10年見通しは? 肺疾患用エアロゾルデリバリーデバイスの世界市場および地域別市場成長の要因は何か? 市場別・地域別で最も急成長する技術は何か? 肺疾患用エアロゾルデリバリーデバイスの市場機会は最終市場規模によってどのように異なるのか? 肺疾患用エアロゾルデリバリーデバイスのタイプ別、用途別の内訳は? 目次1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Pulmonary Disease Aerosol Delivery Devices Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for Pulmonary Disease Aerosol Delivery Devices by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for Pulmonary Disease Aerosol Delivery Devices by Country/Region, 2019, 2023 & 2030 2.2 Pulmonary Disease Aerosol Delivery Devices Segment by Type 2.2.1 Metered- dose Inhalers 2.2.2 Dry-powder Inhalers 2.2.3 Nebulizers 2.3 Pulmonary Disease Aerosol Delivery Devices Sales by Type 2.3.1 Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Type (2019-2024) 2.3.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue and Market Share by Type (2019-2024) 2.3.3 Global Pulmonary Disease Aerosol Delivery Devices Sale Price by Type (2019-2024) 2.4 Pulmonary Disease Aerosol Delivery Devices Segment by Application 2.4.1 Asthma 2.4.2 Chronic Obstructive Pulmonary Disease (COPD) 2.4.3 Cystic Fibrosis (CF) 2.4.4 Idiopathic Pulmonary Fibrosis (IPF) 2.4.5 Others 2.5 Pulmonary Disease Aerosol Delivery Devices Sales by Application 2.5.1 Global Pulmonary Disease Aerosol Delivery Devices Sale Market Share by Application (2019-2024) 2.5.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue and Market Share by Application (2019-2024) 2.5.3 Global Pulmonary Disease Aerosol Delivery Devices Sale Price by Application (2019-2024) 3 Global by Company 3.1 Global Pulmonary Disease Aerosol Delivery Devices Breakdown Data by Company 3.1.1 Global Pulmonary Disease Aerosol Delivery Devices Annual Sales by Company (2019-2024) 3.1.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Company (2019-2024) 3.2 Global Pulmonary Disease Aerosol Delivery Devices Annual Revenue by Company (2019-2024) 3.2.1 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Company (2019-2024) 3.2.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Company (2019-2024) 3.3 Global Pulmonary Disease Aerosol Delivery Devices Sale Price by Company 3.4 Key Manufacturers Pulmonary Disease Aerosol Delivery Devices Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Pulmonary Disease Aerosol Delivery Devices Product Location Distribution 3.4.2 Players Pulmonary Disease Aerosol Delivery Devices Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Pulmonary Disease Aerosol Delivery Devices by Geographic Region 4.1 World Historic Pulmonary Disease Aerosol Delivery Devices Market Size by Geographic Region (2019-2024) 4.1.1 Global Pulmonary Disease Aerosol Delivery Devices Annual Sales by Geographic Region (2019-2024) 4.1.2 Global Pulmonary Disease Aerosol Delivery Devices Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic Pulmonary Disease Aerosol Delivery Devices Market Size by Country/Region (2019-2024) 4.2.1 Global Pulmonary Disease Aerosol Delivery Devices Annual Sales by Country/Region (2019-2024) 4.2.2 Global Pulmonary Disease Aerosol Delivery Devices Annual Revenue by Country/Region (2019-2024) 4.3 Americas Pulmonary Disease Aerosol Delivery Devices Sales Growth 4.4 APAC Pulmonary Disease Aerosol Delivery Devices Sales Growth 4.5 Europe Pulmonary Disease Aerosol Delivery Devices Sales Growth 4.6 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales Growth 5 Americas 5.1 Americas Pulmonary Disease Aerosol Delivery Devices Sales by Country 5.1.1 Americas Pulmonary Disease Aerosol Delivery Devices Sales by Country (2019-2024) 5.1.2 Americas Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2019-2024) 5.2 Americas Pulmonary Disease Aerosol Delivery Devices Sales by Type (2019-2024) 5.3 Americas Pulmonary Disease Aerosol Delivery Devices Sales by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Pulmonary Disease Aerosol Delivery Devices Sales by Region 6.1.1 APAC Pulmonary Disease Aerosol Delivery Devices Sales by Region (2019-2024) 6.1.2 APAC Pulmonary Disease Aerosol Delivery Devices Revenue by Region (2019-2024) 6.2 APAC Pulmonary Disease Aerosol Delivery Devices Sales by Type (2019-2024) 6.3 APAC Pulmonary Disease Aerosol Delivery Devices Sales by Application (2019-2024) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Pulmonary Disease Aerosol Delivery Devices by Country 7.1.1 Europe Pulmonary Disease Aerosol Delivery Devices Sales by Country (2019-2024) 7.1.2 Europe Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2019-2024) 7.2 Europe Pulmonary Disease Aerosol Delivery Devices Sales by Type (2019-2024) 7.3 Europe Pulmonary Disease Aerosol Delivery Devices Sales by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices by Country 8.1.1 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales by Country (2019-2024) 8.1.2 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2019-2024) 8.2 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales by Type (2019-2024) 8.3 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Pulmonary Disease Aerosol Delivery Devices 10.3 Manufacturing Process Analysis of Pulmonary Disease Aerosol Delivery Devices 10.4 Industry Chain Structure of Pulmonary Disease Aerosol Delivery Devices 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Pulmonary Disease Aerosol Delivery Devices Distributors 11.3 Pulmonary Disease Aerosol Delivery Devices Customer 12 World Forecast Review for Pulmonary Disease Aerosol Delivery Devices by Geographic Region 12.1 Global Pulmonary Disease Aerosol Delivery Devices Market Size Forecast by Region 12.1.1 Global Pulmonary Disease Aerosol Delivery Devices Forecast by Region (2025-2030) 12.1.2 Global Pulmonary Disease Aerosol Delivery Devices Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country (2025-2030) 12.3 APAC Forecast by Region (2025-2030) 12.4 Europe Forecast by Country (2025-2030) 12.5 Middle East & Africa Forecast by Country (2025-2030) 12.6 Global Pulmonary Disease Aerosol Delivery Devices Forecast by Type (2025-2030) 12.7 Global Pulmonary Disease Aerosol Delivery Devices Forecast by Application (2025-2030) 13 Key Players Analysis 13.1 GlaxoSmithKline (GSK) 13.1.1 GlaxoSmithKline (GSK) Company Information 13.1.2 GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.1.3 GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 GlaxoSmithKline (GSK) Main Business Overview 13.1.5 GlaxoSmithKline (GSK) Latest Developments 13.2 AstraZeneca 13.2.1 AstraZeneca Company Information 13.2.2 AstraZeneca Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.2.3 AstraZeneca Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 AstraZeneca Main Business Overview 13.2.5 AstraZeneca Latest Developments 13.3 Boehringer Ingelheim 13.3.1 Boehringer Ingelheim Company Information 13.3.2 Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.3.3 Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 Boehringer Ingelheim Main Business Overview 13.3.5 Boehringer Ingelheim Latest Developments 13.4 Mylan 13.4.1 Mylan Company Information 13.4.2 Mylan Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.4.3 Mylan Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 Mylan Main Business Overview 13.4.5 Mylan Latest Developments 13.5 Viatris 13.5.1 Viatris Company Information 13.5.2 Viatris Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.5.3 Viatris Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 Viatris Main Business Overview 13.5.5 Viatris Latest Developments 13.6 Novartis 13.6.1 Novartis Company Information 13.6.2 Novartis Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.6.3 Novartis Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 Novartis Main Business Overview 13.6.5 Novartis Latest Developments 13.7 AptarGroup 13.7.1 AptarGroup Company Information 13.7.2 AptarGroup Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.7.3 AptarGroup Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 AptarGroup Main Business Overview 13.7.5 AptarGroup Latest Developments 13.8 Chiesi Farmaceutici 13.8.1 Chiesi Farmaceutici Company Information 13.8.2 Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.8.3 Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Chiesi Farmaceutici Main Business Overview 13.8.5 Chiesi Farmaceutici Latest Developments 13.9 Koninklijke Philips 13.9.1 Koninklijke Philips Company Information 13.9.2 Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.9.3 Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.9.4 Koninklijke Philips Main Business Overview 13.9.5 Koninklijke Philips Latest Developments 13.10 Teva Pharmaceutical Industries 13.10.1 Teva Pharmaceutical Industries Company Information 13.10.2 Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.10.3 Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.10.4 Teva Pharmaceutical Industries Main Business Overview 13.10.5 Teva Pharmaceutical Industries Latest Developments 13.11 Monaghan Medical 13.11.1 Monaghan Medical Company Information 13.11.2 Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.11.3 Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.11.4 Monaghan Medical Main Business Overview 13.11.5 Monaghan Medical Latest Developments 13.12 OMRON 13.12.1 OMRON Company Information 13.12.2 OMRON Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.12.3 OMRON Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.12.4 OMRON Main Business Overview 13.12.5 OMRON Latest Developments 13.13 PARI International 13.13.1 PARI International Company Information 13.13.2 PARI International Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.13.3 PARI International Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.13.4 PARI International Main Business Overview 13.13.5 PARI International Latest Developments 13.14 Vectura 13.14.1 Vectura Company Information 13.14.2 Vectura Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.14.3 Vectura Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.14.4 Vectura Main Business Overview 13.14.5 Vectura Latest Developments 13.15 H&T Presspart 13.15.1 H&T Presspart Company Information 13.15.2 H&T Presspart Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.15.3 H&T Presspart Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.15.4 H&T Presspart Main Business Overview 13.15.5 H&T Presspart Latest Developments 14 Research Findings and Conclusion
SummaryPulmonary Disease Aerosol Delivery Devices are medical instruments designed to administer medications directly to the lungs in the form of aerosolized particles, facilitating the treatment of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. These devices include nebulizers, metered-dose inhalers (MDIs), and dry powder inhalers (DPIs), each tailored to deliver precise doses of medication efficiently. By converting liquid medication into a fine mist or aerosol, these devices enable rapid absorption through the respiratory tract, providing quick relief of symptoms and improving lung function. They are essential for managing chronic respiratory diseases, ensuring patients receive effective and targeted therapy with minimal systemic side effects. Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Pulmonary Disease Aerosol Delivery Devices Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for Pulmonary Disease Aerosol Delivery Devices by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for Pulmonary Disease Aerosol Delivery Devices by Country/Region, 2019, 2023 & 2030 2.2 Pulmonary Disease Aerosol Delivery Devices Segment by Type 2.2.1 Metered- dose Inhalers 2.2.2 Dry-powder Inhalers 2.2.3 Nebulizers 2.3 Pulmonary Disease Aerosol Delivery Devices Sales by Type 2.3.1 Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Type (2019-2024) 2.3.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue and Market Share by Type (2019-2024) 2.3.3 Global Pulmonary Disease Aerosol Delivery Devices Sale Price by Type (2019-2024) 2.4 Pulmonary Disease Aerosol Delivery Devices Segment by Application 2.4.1 Asthma 2.4.2 Chronic Obstructive Pulmonary Disease (COPD) 2.4.3 Cystic Fibrosis (CF) 2.4.4 Idiopathic Pulmonary Fibrosis (IPF) 2.4.5 Others 2.5 Pulmonary Disease Aerosol Delivery Devices Sales by Application 2.5.1 Global Pulmonary Disease Aerosol Delivery Devices Sale Market Share by Application (2019-2024) 2.5.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue and Market Share by Application (2019-2024) 2.5.3 Global Pulmonary Disease Aerosol Delivery Devices Sale Price by Application (2019-2024) 3 Global by Company 3.1 Global Pulmonary Disease Aerosol Delivery Devices Breakdown Data by Company 3.1.1 Global Pulmonary Disease Aerosol Delivery Devices Annual Sales by Company (2019-2024) 3.1.2 Global Pulmonary Disease Aerosol Delivery Devices Sales Market Share by Company (2019-2024) 3.2 Global Pulmonary Disease Aerosol Delivery Devices Annual Revenue by Company (2019-2024) 3.2.1 Global Pulmonary Disease Aerosol Delivery Devices Revenue by Company (2019-2024) 3.2.2 Global Pulmonary Disease Aerosol Delivery Devices Revenue Market Share by Company (2019-2024) 3.3 Global Pulmonary Disease Aerosol Delivery Devices Sale Price by Company 3.4 Key Manufacturers Pulmonary Disease Aerosol Delivery Devices Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Pulmonary Disease Aerosol Delivery Devices Product Location Distribution 3.4.2 Players Pulmonary Disease Aerosol Delivery Devices Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Pulmonary Disease Aerosol Delivery Devices by Geographic Region 4.1 World Historic Pulmonary Disease Aerosol Delivery Devices Market Size by Geographic Region (2019-2024) 4.1.1 Global Pulmonary Disease Aerosol Delivery Devices Annual Sales by Geographic Region (2019-2024) 4.1.2 Global Pulmonary Disease Aerosol Delivery Devices Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic Pulmonary Disease Aerosol Delivery Devices Market Size by Country/Region (2019-2024) 4.2.1 Global Pulmonary Disease Aerosol Delivery Devices Annual Sales by Country/Region (2019-2024) 4.2.2 Global Pulmonary Disease Aerosol Delivery Devices Annual Revenue by Country/Region (2019-2024) 4.3 Americas Pulmonary Disease Aerosol Delivery Devices Sales Growth 4.4 APAC Pulmonary Disease Aerosol Delivery Devices Sales Growth 4.5 Europe Pulmonary Disease Aerosol Delivery Devices Sales Growth 4.6 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales Growth 5 Americas 5.1 Americas Pulmonary Disease Aerosol Delivery Devices Sales by Country 5.1.1 Americas Pulmonary Disease Aerosol Delivery Devices Sales by Country (2019-2024) 5.1.2 Americas Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2019-2024) 5.2 Americas Pulmonary Disease Aerosol Delivery Devices Sales by Type (2019-2024) 5.3 Americas Pulmonary Disease Aerosol Delivery Devices Sales by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Pulmonary Disease Aerosol Delivery Devices Sales by Region 6.1.1 APAC Pulmonary Disease Aerosol Delivery Devices Sales by Region (2019-2024) 6.1.2 APAC Pulmonary Disease Aerosol Delivery Devices Revenue by Region (2019-2024) 6.2 APAC Pulmonary Disease Aerosol Delivery Devices Sales by Type (2019-2024) 6.3 APAC Pulmonary Disease Aerosol Delivery Devices Sales by Application (2019-2024) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Pulmonary Disease Aerosol Delivery Devices by Country 7.1.1 Europe Pulmonary Disease Aerosol Delivery Devices Sales by Country (2019-2024) 7.1.2 Europe Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2019-2024) 7.2 Europe Pulmonary Disease Aerosol Delivery Devices Sales by Type (2019-2024) 7.3 Europe Pulmonary Disease Aerosol Delivery Devices Sales by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices by Country 8.1.1 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales by Country (2019-2024) 8.1.2 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Revenue by Country (2019-2024) 8.2 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales by Type (2019-2024) 8.3 Middle East & Africa Pulmonary Disease Aerosol Delivery Devices Sales by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Pulmonary Disease Aerosol Delivery Devices 10.3 Manufacturing Process Analysis of Pulmonary Disease Aerosol Delivery Devices 10.4 Industry Chain Structure of Pulmonary Disease Aerosol Delivery Devices 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Pulmonary Disease Aerosol Delivery Devices Distributors 11.3 Pulmonary Disease Aerosol Delivery Devices Customer 12 World Forecast Review for Pulmonary Disease Aerosol Delivery Devices by Geographic Region 12.1 Global Pulmonary Disease Aerosol Delivery Devices Market Size Forecast by Region 12.1.1 Global Pulmonary Disease Aerosol Delivery Devices Forecast by Region (2025-2030) 12.1.2 Global Pulmonary Disease Aerosol Delivery Devices Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country (2025-2030) 12.3 APAC Forecast by Region (2025-2030) 12.4 Europe Forecast by Country (2025-2030) 12.5 Middle East & Africa Forecast by Country (2025-2030) 12.6 Global Pulmonary Disease Aerosol Delivery Devices Forecast by Type (2025-2030) 12.7 Global Pulmonary Disease Aerosol Delivery Devices Forecast by Application (2025-2030) 13 Key Players Analysis 13.1 GlaxoSmithKline (GSK) 13.1.1 GlaxoSmithKline (GSK) Company Information 13.1.2 GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.1.3 GlaxoSmithKline (GSK) Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 GlaxoSmithKline (GSK) Main Business Overview 13.1.5 GlaxoSmithKline (GSK) Latest Developments 13.2 AstraZeneca 13.2.1 AstraZeneca Company Information 13.2.2 AstraZeneca Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.2.3 AstraZeneca Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 AstraZeneca Main Business Overview 13.2.5 AstraZeneca Latest Developments 13.3 Boehringer Ingelheim 13.3.1 Boehringer Ingelheim Company Information 13.3.2 Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.3.3 Boehringer Ingelheim Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 Boehringer Ingelheim Main Business Overview 13.3.5 Boehringer Ingelheim Latest Developments 13.4 Mylan 13.4.1 Mylan Company Information 13.4.2 Mylan Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.4.3 Mylan Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 Mylan Main Business Overview 13.4.5 Mylan Latest Developments 13.5 Viatris 13.5.1 Viatris Company Information 13.5.2 Viatris Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.5.3 Viatris Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 Viatris Main Business Overview 13.5.5 Viatris Latest Developments 13.6 Novartis 13.6.1 Novartis Company Information 13.6.2 Novartis Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.6.3 Novartis Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 Novartis Main Business Overview 13.6.5 Novartis Latest Developments 13.7 AptarGroup 13.7.1 AptarGroup Company Information 13.7.2 AptarGroup Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.7.3 AptarGroup Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 AptarGroup Main Business Overview 13.7.5 AptarGroup Latest Developments 13.8 Chiesi Farmaceutici 13.8.1 Chiesi Farmaceutici Company Information 13.8.2 Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.8.3 Chiesi Farmaceutici Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Chiesi Farmaceutici Main Business Overview 13.8.5 Chiesi Farmaceutici Latest Developments 13.9 Koninklijke Philips 13.9.1 Koninklijke Philips Company Information 13.9.2 Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.9.3 Koninklijke Philips Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.9.4 Koninklijke Philips Main Business Overview 13.9.5 Koninklijke Philips Latest Developments 13.10 Teva Pharmaceutical Industries 13.10.1 Teva Pharmaceutical Industries Company Information 13.10.2 Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.10.3 Teva Pharmaceutical Industries Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.10.4 Teva Pharmaceutical Industries Main Business Overview 13.10.5 Teva Pharmaceutical Industries Latest Developments 13.11 Monaghan Medical 13.11.1 Monaghan Medical Company Information 13.11.2 Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.11.3 Monaghan Medical Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.11.4 Monaghan Medical Main Business Overview 13.11.5 Monaghan Medical Latest Developments 13.12 OMRON 13.12.1 OMRON Company Information 13.12.2 OMRON Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.12.3 OMRON Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.12.4 OMRON Main Business Overview 13.12.5 OMRON Latest Developments 13.13 PARI International 13.13.1 PARI International Company Information 13.13.2 PARI International Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.13.3 PARI International Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.13.4 PARI International Main Business Overview 13.13.5 PARI International Latest Developments 13.14 Vectura 13.14.1 Vectura Company Information 13.14.2 Vectura Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.14.3 Vectura Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.14.4 Vectura Main Business Overview 13.14.5 Vectura Latest Developments 13.15 H&T Presspart 13.15.1 H&T Presspart Company Information 13.15.2 H&T Presspart Pulmonary Disease Aerosol Delivery Devices Product Portfolios and Specifications 13.15.3 H&T Presspart Pulmonary Disease Aerosol Delivery Devices Sales, Revenue, Price and Gross Margin (2019-2024) 13.15.4 H&T Presspart Main Business Overview 13.15.5 H&T Presspart Latest Developments 14 Research Findings and Conclusion
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポート
LP Information 社の最新刊レポート本レポートと同じKEY WORD(devices)の最新刊レポートよくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/06 10:26 144.24 円 160.68 円 192.83 円 |